ERBB2 and breast carcinoma: Results from the Phase I HEROHE challenge showed that HER2 status in breast cancer can be predicted solely from routine hematoxylin and eosin (H&E) stained slides, circumventing the need for special immunohistochemistry (IHC) techniques[167].